Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: gleevec + web + web   Related to the article below (Last Update: 5/5/2008)

AROUND TOWN
Dodge City Daily Globe, KS - Apr 26, 2008
That research has led to advances such as bone marrow transplants, the use of drugs such as Tamoxifen and Gleevec on certain cancers, and the Pap smear ...
Novartis Pays $11 Billion for Stake in Nestle's Alcon (Update3)
Bloomberg - Apr 7, 2008
Those medicines were meant to replace income from heart drug Diovan and cancer treatment Gleevec. Novartis, which has lost 16 percent this year, ...PINK:NVSEF - VTX:NESN
Fox Chase researchers discover a method for clamping down on a ...
Genetic Engineering News (press release), NY - Apr 18, 2008
The cancer drug Gleevec, for example, is unusually selective for its target by binding to a region outside of the active site that is less common among ...
Source: Google News

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor -
NP Shah, C Tran, FY Lee, P Chen, D Norris, CL … - Science, 2004 - sciencemag.org
... that you are using a browser that does not support current Web standards ... Resistance
to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid ...

Research on Resistance to Cancer Drug Gleevec -
CL Sawyers - Science, 2001 - sciencemag.org
... in: ISI Web of Science (16). Request permission to use this article. ... [DOI:
10.1126/science.294.5548.1834b] Letters. Research on Resistance to Cancer Drug Gleevec ...

Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant … -
JAE Irving, SO'Brien, AL Lennard, L Minto, F Lin, … - Clinical Chemistry, 2004 - Am Assoc Clin Chem
... The ABL tyrosine kinase inhibitor imatinib (STI571, Glivec, Gleevec) has produced
dramatic clinical responses in most patients with chronic myeloid leukemia (1 ...

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their … -
J Kuroda, H Puthalakath, MS Cragg, PN Kelly, P … - Proceedings of the National Academy of Sciences, 2006 - National Acad Sciences
... 13, which is published as supporting information on the PNAS web site). In addition,
imatinib caused Bmf up-regulation in lines of all genotypes (although ...

… overexpression in t (8; 21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec -
YY Wang, GB Zhou, T Yin, B Chen, JY Shi, WX Liang, … - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences
... to TK inhibitor Gleevec/STI-571/imatinib mesylate (26), the Gleevec response of ... 2,
which is published as supporting information on the PNAS web site), and the ...

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance -
K Gumireddy, SJ Baker, SC Cosenza, P John, AD Kang … - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences
... equation with a constant amount of ATP and various amounts of substrate and imatinib. ...
Table 2, which is published as supporting information on the PNAS web site ...

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with … -
P B?mming, J Andersson, JM Meis-Kindblom, H … - British Journal of Cancer, 2003 - nature.com
Full text access provided to Googlebot Access by Web Services. ... L, Borden E. (2002)
Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for ...

Absolute Bioavailability of Imatinib (Glivec?) Orally versus Intravenous Infusion -
B Peng, C Dutreix, G Mehring, MJ Hayes, M Ben-Am, … - The Journal of Clinical Pharmacology, 2004 - jcp.sagepub.com
... 15. Gschwind HP, Pfaar U, Waldmeier F, Ben-AM M, Peng B, Gross G: Metabolism
and disposition of Gleevec TM (STI571) in healthy volunteers. ...

The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF- … -
AM Wolf, D Wolf, H Rumpold, S Ludwiczek, B Enrich, … - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences
... 11 A and B, which is published as supporting information on the PNAS web site).
To rule out an inhibitory effect of imatinib on Con A-induced T cell activation ...

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug -
R Capdeville, E Buchdunger, J Zimmermann, A Matter … - Nature Reviews Drug Discovery, 2002 - nature.com
Full text access provided to Googlebot Access by Web Services. ... Glivec (STI571,
imatinib), a rationally developed, targeted anticancer drug. ...

Source: Google Scholar

Gleevec, the targeted cancer pill, delivers more good news to patients

 

PORTLAND, Ore. – Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.

“Data at this weekend’s meeting continues to show how much Gleevec has completely changed the outlook for so many, many patients facing cancer,” said Brian Druker, M.D., director of the OHSU Cancer Institute.

At the plenary session of the annual meeting of the American Society of Hematology researchers delivered news that Gleevec has been shown to improve outcomes for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Ph+ ALL is the childhood leukemia with the worst prognosis and the Children’s Oncology Group study shows that adding Gleevec to the treatment almost completely reverses this poor prognosis. The Children’s Oncology Group is a worldwide clinical trial cooperative supported by the National Cancer Institute, a branch of the National Institutes of Health.

Also released at the conference is new data from the largest clinical trial in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that showed Gleevec, with long-term use, can prevent progression to advanced stages of the disease.

Six-year results of the International Randomized Interferon versus STI571 (IRIS) study for which Druker served as principal investigator, demonstrated that continuous treatment with Gleevec produced a declining rate of relapse over time. The downward trend in the risk of disease progression while on Gleevec has continued since year two of the study. Remarkably, between years five and six, no patients progressed to an advanced phase of the disease.

“The news about Gleevec and the childhood leukemia study as well as the six-year IRIS study that shows there is no progression to advanced phase in CML means that more and more patients are surviving, despite being diagnosed with these cancers,” said Druker, JELD-WEN Chair of Leukemia Research, Howard Hughes Medical Institute Investigator and member of the National Academy of Sciences. He also is a professor of medicine (hematology and medical oncology), cell and developmental biology, and biochemistry and molecular biology in the OHSU School of Medicine.

Gleevec has also been approved for the treatment of gastrointestinal stromal tumors, pediatric CML, as well as five additional rare cancers.

###

Particulars: Michael Heinrich, M.D., professor of medicine (hematology/medical oncology) in the OHSU School of Medicine and the Portland Veteran’s Affairs medical Center, and a member of the OHSU Cancer Institute, has been the principal investigator in research studies involving GIST and Gleevec.

The OHSU Cancer Institute is the only National Cancer Institute-designated center between Sacramento and Seattle. It comprises some 120 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for cancer patients. In the lab, basic scientists examine cancer cells and normal cells to uncover molecular abnormalities that cause the disease. This basic science informs more than 200 clinical trials conducted at the OHSU Cancer Institute.

Contact: Christine Decker, 503 494-8231; deckerch@ohsu.edu for interview opportunities with Brian Druker, M.D., co-developer of Gleevec with Novartis Pharmaceuticals.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.